Trials / Completed
CompletedNCT00120536
Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2005-07-18
- Last updated
- 2017-05-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00120536. Inclusion in this directory is not an endorsement.